Current diagnostic criteria for cardiac sarcoidosis (CS) rely on non-invasive imaging tools including positron emission tomography (PET-CT) and cardiac magnetic resonance (CMR). The aim of this study was to assess the prevalence of discordant myocardial inflammation between PET-CT and CMR in patients with known cardiac sarcoidosis. We retrospectively identified patients with both F-FDG PET-CT and CMR who had histology-proven sarcoidosis (N = 148). Among these 25 (17%) had abnormal F-FDG metabolism with normal tissue characterization by CMR. Of these, 13 (9%) had the studies concomitantly within 180 days (median 5 days, IQR 1-31). During median follow up of 7 years, 3 (23%) deaths were documented. Although prospective studies are required to address the best imaging approach for cardiac inflammation, our observation that some patients with CS have evidence of disease activity on PET-CT, but not on limited CMR without mapping suggests that a negative limited CMR may not fully exclude CS.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11442761 | PMC |
| http://dx.doi.org/10.1186/s41824-024-00218-4 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The time is now: Identifying optimal imaging strategies to monitor cardiac sarcoidosis activity.
J Nucl Cardiol
January 2025
Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Impact of Sarcoidosis in Patients Undergoing Aortic Valve Replacement: Insight from Nationwide Readmission Database 2016-2019.
Indian Heart J
January 2025
Franciscan Health, Lafayette, Indiana; Krannert Cardiovascular Research Center, Indiana University School of Medicine, Indianapolis, Indiana. Electronic address:
It is not well-known if valve replacement outcomes differ in patients with sarcoidosis, especially in aortic valve intervention where the pressure gradients are physiologically high. In this retrospective study, we included all patients who underwent surgical/transcatheter aortic valve replacement from the National Readmission Database (2016-2019) and then divided them into those with and without sarcoidosis. Logistic and cox proportional hazard regression models were used.
View Article and Find Full Text PDFAtrial arrhythmias with mediastinal lymphadenopathy presentation of isolated atrial myocarditis.
J Arrhythm
February 2025
Department of Electrophysiology, Department of Cardiology AIG Institute of Cardiac Sciences and Research Hyderabad India.
Objectives: We present a case series of patients with granulomatous myocarditis presenting as atrial arrhythmias accompanied by lymphadenopathy.
Background: Atrial myocarditis (AM) may be the cause of atrial fibrillation (AF) in patients without risk factors.
Methods: Patients with atrial fibrillation without risk factors underwent 18F-Fluorodeoxyglucose positron emission tomography (18F-FDG-PET).
Atrial FDG Uptake: Etiologies, Clinical Significance, and Implications.
Curr Cardiol Rep
January 2025
Department of Medical Imaging, Montreal Heart Institute, Montréal, Québec, Canada.
Purpose Of Review: This review aims to explore the clinical significance of atrial fluorodeoxyglucose (FDG) uptake observed in positron emission tomography (PET) scans, focusing on its association with atrial fibrillation (AF), cardiac sarcoidosis, and myocarditis. We discuss the implications of atrial uptake for patient management and prognosis.
Recent Findings: Recent studies have demonstrated that atrial FDG uptake is frequently present in patients with AF, particularly those with persistent AF, and is linked to increased risks of stroke and poorer outcomes after ablation.
Therapeutic doses of efzofitimod demonstrate efficacy in pulmonary sarcoidosis.
ERJ Open Res
January 2025
Division of Pulmonary and Critical Care Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.
Background: In a phase 1b/2a clinical trial of efzofitimod in patients with corticosteroid-requiring pulmonary sarcoidosis, treatment resulted in dose-dependent improvement in key end-points. We undertook a analysis pooling dose arms that achieved therapeutic concentrations of efzofitimod (Therapeutic group) those that did not (Subtherapeutic group).
Methods: Peripheral blood mononuclear cells incubated with tuberculin-coated beads were exposed to varying concentrations of efzofitimod in an assay to determine concentrations that inhibited granuloma formation.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!